The North America Obesity Intervention Devices Market should witness market growth of 4.6% CAGR during the forecast period (2023-2029).
The rise in the number of medications launched for obesity intervention devices are the main factors driving the growth of the market. Obesity is characterized by an excess of body fat that has built up to the point that it is harmful to one's health. Typically, it is determined by a person's body mass index (BMI), which is computed using their height and weight.
Obesity is defined as a BMI of 30 or higher. By reducing how much food a person can comfortably eat, obesity intervention devices help people lose weight. Therefore, it is anticipated that the market will expand due to the rising prevalence of obesity. The market size is predicted to increase as the incidence of type 2 diabetes rises. The most typical kind of diabetes is type 2. Insulin resistance, which occurs when the body does not fully respond to insulin, is typically a defining feature.
Because insulin cannot function properly, blood glucose levels continue to increase, causing an increase in insulin release. Type 2 diabetes has obesity as a key risk factor. Insulin resistance, a major risk factor for type 2 diabetes, is more likely to develop in obese people. Chronic inflammation and obesity are related, and insulin resistance can result from chronic inflammation. Additionally, leptin is one hormone that is elevated in obese individuals and has been linked to a higher risk of type 2 diabetes.
Businesses should be concerned about the impact of unhealthy eating habits, inactivity, and obesity. Two out of every three adults in Canada are overweight or obese, according to Statistics Canada. Furthermore, over the past 25 years, there has been a significant rise in the prevalence of childhood obesity. With the exception of those in preschool, the increase was seen in both the male and female demographics and throughout all age groups. Additionally, to reach their full potential for growth and development, more than 50% of Canadian kids and teenagers do not participate in enough physical activity. As a result, it is anticipated that there will be greater demand for obesity intervention devices in the local market due to the rising prevalence of obesity among the population in the region.
The US market dominated the North America Obesity Intervention Devices Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $89.7 million by 2029. The Canada market is poised to grow at a CAGR of 7% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 6% during (2023-2029).
Based on End-user, the market is segmented into Hospitals and Clinics & Others. Based on Device, the market is segmented into Gastric Bands, Gastric Balloon and Gastric Stimulation System. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Apollo Endosurgery, Inc. (Boston Scientific Corporation), ReShape Lifesciences, Inc., AbbVie, Inc., Allurion Technologies, Inc., Spatz FGIA, Inc, Cousin Surgery, A.M.I. GmbH, ENDALIS, and GI Dynamics, Inc.
The rise in the number of medications launched for obesity intervention devices are the main factors driving the growth of the market. Obesity is characterized by an excess of body fat that has built up to the point that it is harmful to one's health. Typically, it is determined by a person's body mass index (BMI), which is computed using their height and weight.
Obesity is defined as a BMI of 30 or higher. By reducing how much food a person can comfortably eat, obesity intervention devices help people lose weight. Therefore, it is anticipated that the market will expand due to the rising prevalence of obesity. The market size is predicted to increase as the incidence of type 2 diabetes rises. The most typical kind of diabetes is type 2. Insulin resistance, which occurs when the body does not fully respond to insulin, is typically a defining feature.
Because insulin cannot function properly, blood glucose levels continue to increase, causing an increase in insulin release. Type 2 diabetes has obesity as a key risk factor. Insulin resistance, a major risk factor for type 2 diabetes, is more likely to develop in obese people. Chronic inflammation and obesity are related, and insulin resistance can result from chronic inflammation. Additionally, leptin is one hormone that is elevated in obese individuals and has been linked to a higher risk of type 2 diabetes.
Businesses should be concerned about the impact of unhealthy eating habits, inactivity, and obesity. Two out of every three adults in Canada are overweight or obese, according to Statistics Canada. Furthermore, over the past 25 years, there has been a significant rise in the prevalence of childhood obesity. With the exception of those in preschool, the increase was seen in both the male and female demographics and throughout all age groups. Additionally, to reach their full potential for growth and development, more than 50% of Canadian kids and teenagers do not participate in enough physical activity. As a result, it is anticipated that there will be greater demand for obesity intervention devices in the local market due to the rising prevalence of obesity among the population in the region.
The US market dominated the North America Obesity Intervention Devices Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $89.7 million by 2029. The Canada market is poised to grow at a CAGR of 7% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 6% during (2023-2029).
Based on End-user, the market is segmented into Hospitals and Clinics & Others. Based on Device, the market is segmented into Gastric Bands, Gastric Balloon and Gastric Stimulation System. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Apollo Endosurgery, Inc. (Boston Scientific Corporation), ReShape Lifesciences, Inc., AbbVie, Inc., Allurion Technologies, Inc., Spatz FGIA, Inc, Cousin Surgery, A.M.I. GmbH, ENDALIS, and GI Dynamics, Inc.
Scope of the Study
By End-user
- Hospitals
- Clinics & Others
By Device
- Gastric Bands
- Gastric Balloon
- Gastric Stimulation System
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- Apollo Endosurgery, Inc. (Boston Scientific Corporation)
- ReShape Lifesciences, Inc.
- AbbVie, Inc.
- Allurion Technologies, Inc.
- Spatz FGIA, Inc
- Cousin Surgery
- A.M.I. GmbH
- ENDALIS
- GI Dynamics, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Obesity Intervention Devices Market by End-user
Chapter 4. North America Obesity Intervention Devices Market by Device
Chapter 5. North America Obesity Intervention Devices Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Apollo Endosurgery, Inc. (Boston Scientific Corporation)
- ReShape Lifesciences, Inc.
- AbbVie, Inc.
- Allurion Technologies, Inc.
- Spatz FGIA, Inc
- Cousin Surgery
- A.M.I. GmbH
- ENDALIS
- GI Dynamics, Inc.
Methodology
LOADING...
